Transcode Therapeutics RNAZ
NASDAQ RNAZ
$1.40 +0.05 (+3.70%)
At close: Nov 11, 2026 · 4:00 PM EST

Transcode Therapeutics (RNAZ) Convertible Debt (2020 - 2021)

Updated

Transcode Therapeutics (RNAZ) reported Convertible Debt of $2.13 million for Q2 2021.

Analysis

Transcode Therapeutics (RNAZ) Convertible Debt (2020 - 2021) Analysis & Trends

At the end of FY2020, Transcode Therapeutics posted Convertible Debt of $2.09 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Transcode Therapeutics 1.37 Mn -40.52 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 2.13 Mn
Dec 31, 2020 2.09 Mn
API Access

Transcode Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=RNAZ&period=max&api_key=YOUR_API_KEY